Drug discovery

#Drug discovery #Funding #Healthcare #Investment #Life sciences #Public health

Drug discovery investors: Who’s spending? 

While the research, results and trials often take centre-stage when it comes to drug discovery and development reporting, DDW’s Megan Thomas spotlights the funding and investments which make this possible.   1. US researcher awarded $3.6 million to study antibiotic resistance  Sanford Burnham Prebys professor Andrei Osterman, Ph.D., has… Read More

#Business & Investment #Editor's Choice #Exclusive Content #News

#Drug discovery #Genomics #Life sciences #Molecular Biology

Finding the right cancer drug with high-content screening

Listen to this article on the DDW Podcast: Lassi Paavolainen, Principal Investigator at the Institute for Molecular Medicine Finland (FIMM), Vilja Pietiäinen, Adjunct Professor in Cell and Molecular Biology, and Amanda Jones, Life Science Research Strategy Leader at PerkinElmer explain how functional precision medicine using ex vivo drug testing… Read More

#Editor's Choice #News

#Drug discovery #Events #Lab automation #SLAS2022

What to expect from SLAS2022 

SLAS2022 in Boston is moving ahead as an in-person event with a hybrid component from February 5-9, 2022 at Boston Convention & Exhibition Center, which unsurprisingly has many from the drug discovery industry excited, including the DDW team, who will be stationed at Booth 1945.   DDW has teamed up… Read More

#Exclusive Content #News #Trending News

#Biology #Drug discovery #Protein chemistry / Proteomics #Therapeutics

Why the emergence of targeted protein degradation is so exciting 

Listen to this article on the DDW Podcast: Last year a new translational research centre was established to bolster the University of Dundee’s drug discovery position. The Centre for Targeted Protein Degradation (CeTPD) would allow Professor Alessio Ciulli and colleagues to expand their pioneering work in an area that has… Read More

#hidden

#Comment #Covid-19 #Drug discovery #Podcast

From here to there: What lies ahead for drug discovery – podcast

This is the latest episode of the free DDW podcast, “From here to there: What lies ahead for drug discovery”. It covers two narrated articles written for Volume 22, Issue 3 – Summer 2021 of DDW and read aloud by Megan Thomas. The articles are called “The complexity of disease… Read More

#News

#Drug discovery

This week in drug discovery (17-21 January) 

News round-up by DDW’s Megan Thomas for 17-21 January, 2022  When it comes to drug discovery and development, it’s all about the research, the breakthroughs and the next step. DDW’s Megan Thomas has rounded up five stories which highlight this theme of progress.  1. Read More

#News #Trending News

#Biotechnology #Drug discovery #Therapeutics

Drug discovery movers: who’s going where? 

The new year is underway and with it comes a raft of movement within some of the industry’s key businesses. DDW’s Megan Thomas rounds up seven new additions to the sector.  Dr Charles Woler (Sygnature Discovery, UK)  Sygnature Discovery, provider of drug discovery solutions, has appointed Dr Charles Woler as Chairman. Dr Woler has… Read More

#News #Trending News

#Collaboration #Drug candidates #Drug discovery

Drug discovery collaboration tackles metabolic diseases

Evotec has entered into a drug discovery collaboration with Eli Lilly and Company (Lilly) in the field of metabolic diseases with a focus on kidney diseases and diabetes.  The collaboration  The collaboration leverages Evotec’s metabolic disease experience, as well as its kidney disease patient database,… Read More

#News

#AI / data analytics / healthtech / informatics #Comment #Drug discovery #SLAS2022

Comment: AI-powered drug discovery 

The Winter issue of the Drug Discovery World Magazine is accompanied by an exclusive DDW & SLAS2022 supplement ahead of SLAS2022 in Boston, US on 5-9 February. As we all look forward to the expertise at the event, DDW’s Megan Thomas outlines the highlights of the first SLAS 2021 AI-Powered Drug Discovery… Read More

#Editor's Choice #Exclusive Content #News #Opinion

#AI / data analytics / healthtech / informatics #Drug discovery

DDW exclusive: 2022 drug discovery challenges and opportunities 

DDW’s Megan Thomas spoke to key decision-makers from the drug discovery industry about their predictions on what 2022 holds for our sector, which can be downloaded and viewed for free from the DDW App for users of Apple or Android devices. “Carefully distinguishing true opportunities from passing fads will… Read More

#News #Trending News

Boston
#Comment #Drug discovery #Drug innovation #Lab automation #SLAS2022

From the editor: Being part of the innovation 

The Winter issue of the Drug Discovery World Magazine is accompanied by an exclusive DDW & SLAS2022 supplement ahead of SLAS2022 in Boston, US on 5-9 February. DDW Editor in Chief Lu Rahman comments.  There is huge excitement within the DDW team regarding the SLAS2022 International Conference and Exhibition in Boston on 5-9… Read More

#Editor's Choice #Exclusive Content #News

Artificial Intelligence
#AI / data analytics / healthtech / informatics #Collaboration #Drug discovery

BenevolentAI announces collaboration with AstraZeneca 

BenevolentAI, a clinical-stage AI drug discovery company, has expanded its AI-driven drug discovery collaboration with AstraZeneca, doubling the number of disease areas being explored through the partnership.   The expansion  The expansion builds on the collaboration initiated in 2019 and adds systemic lupus erythematosus (SLE) and… Read More

#News

#Drug discovery #Pharmaceuticals

Pharmaceutical executive takes the Synature Discovery reins 

Sygnature Discovery, providers of drug discovery solutions, has appointed Dr Charles Woler as Chairman.  Woler’s career Dr Woler has held multiple key roles in the sector, including CEO at Roche France, Executive Chairman for Europe at SmithKline Beecham, and CEO at Cadus Pharmaceutical in the US.   Official comments … Read More

#News #Trending News

#Comment #Covid-19 #Drug development #Drug discovery

From the editor: Courage and curiosity in collaboration 

Collaboration within the drug discovery sector is well documented, says Lu Rahman. During the Covid-19 pandemic we have seen great examples. Take Pfizer and BioNTech or the work between Carterra and Eli Lilly Company to create bamlanivimab, a Covid-19 therapeutic. Collaborative work has created vaccines and therapeutics which are… Read More

#Editor's Choice #News #Opinion

#Drug discovery #Drug targets #Drug technology #Pharmaceuticals #Quantum computing

How quantum computing can benefit drug discovery 

Listen to this article on the DDW Podcast: Brad Loren, Matthew Marrone, and Christopher Singer, of intellectual property and technology law firm McAndrews, Held & Malloy, on quantum computing and its benefits to drug discovery.  Explaining quantum computing and its promise  Before we… Read More

#Editor's Choice #Exclusive Content #News #Opinion #Trends & Analysis

#AI #Collaboration #Drug development #Drug discovery

Exscientia and Sanofi to develop AI-driven medicines 

Sanofi and Exscientia have announced a research collaboration and license agreement to develop up to 15 novel small molecule candidates across oncology and immunology, leveraging Exscientia’s end-to-end AI-driven platform utilising actual patient samples.   Background  The companies have been working together since 2016 and in 2019, Sanofi in-licensed Exscientia’s novel bispecific small… Read More

#News